The API Factory That Made Headlines (Not All Good)

The Rebranded Pharma Ingredient Play That’s Trying Really Hard

Let’s talk about Alivus Life Sciences. No, wait — let’s first establish that it used to be called Glenmark Life Sciences until January 2026, when Nirma Limited (the diversified conglomerate that makes detergent and cement and owns half the stock) decided a rebrand was in order. Hence: Alivus. It sounds like a Roman general, a wellness app, or something you’d buy at a Goan rave. It is none of these. It’s a contract API manufacturer with a ₹11,537 crore market cap, 165 unique molecules, and more regulatory scrutiny than a three-Michelin-star kitchen.

The company makes Active Pharmaceutical Ingredients — the raw materials that drug companies turn into actual medicines. Think of them as the flour supplier to a bakery. Boring? Possibly. Profitable? Very much yes. ROCE of 24.9%, gross margins bouncing between 54–59%, EBITDA margins at a 5-year average of 30%, and an operating model so clean that even the CFO probably gets bored reading the annual report.

Q3 FY26 was supposed to be a quiet quarter of steady execution. And it was — until February 14, 2026, when a fire broke out at the Dahej facility, suspended production, injured three people, and forced management to issue regulatory disclosures like they were handing out candy on Halloween. Then came the GST order. Then came the customs order. Then came another GST order. Welcome to 2026, where your API factory is either printing 36% margins or dealing with paperwork. Sometimes both.

So here’s the deal: Alivus just changed its name. Its largest shareholder (Nirma) owns 74.9% and has turned it into a strategic pharma asset. The business model is bulletproof. The financials are strong. The margins are inflating in real time. But — and this is a spicy “but” — the regulatory environment is showing teeth. In this article, we break down the numbers, roast the regulatory chaos, and ask the question every investor needs to answer: Are you buying EBITDA margins or regulatory risk?

165 Molecules. 85% From Regulated Markets. 100% Unsexy.

Alivus manufactures high-value, non-commoditized active pharmaceutical ingredients. Translation: they don’t make paracetamol or ibuprofen (commodity APIs where every second country makes them). They make specialized APIs for cardiovascular drugs (32 molecules), CNS medicines (26 molecules), diabetes (11 molecules), oncology (13 molecules), and pain management (6 molecules). These are the chemicals that go into Lipitor, Januvia, certain cancer drugs, and antiparasitics. One customer is Glenmark Pharma, their former parent, which accounts for 28% of revenue and has a long-term supply contract through FY29.

The business is split roughly 85% regulated markets (US, Europe, Japan, Canada, South Korea) and 15% emerging markets. They operate four manufacturing facilities in Ankleshwar, Dahej, Mohol, and Kurkumbh across Gujarat and Maharashtra. Three have USFDA approval. All hold global regulatory certifications. Capacity utilization runs at 90–95% consistently. The company also runs a CDMO segment (Contract Development and Manufacturing Operations) where they develop and manufacture custom APIs for innovator drug companies — which is growing fast and carries higher margins once projects lock in.

Revenue concentration is a thing: top 10 APIs contribute 49% of revenues (down from 51% last year, so diversification is happening). But that also means 28% of revenue comes from one customer (GPL). The company mitigates this with ~2,250 customers globally and a disciplined approach to customer concentration. R&D spend sits at 3.4–3.7% of sales (consistently above peers), focused on process chemistry, green initiatives, and high-potency APIs where margins are fattest.

Q3 FY26: Record Revenue. Record Margins. Record Paperwork Drama.